Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention
Standard
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. / Schneeweiss, Andreas; Lux, Michael P; Janni, Wolfgang; Hartkopf, Andreas D; Nabieva, Naiba; Taran, Florin-Andrei; Overkamp, Friedrich; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Wöckel, Achim; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Wallwiener, Diethelm; Brucker, Sara Y; Schütz, Florian; Fasching, Peter A; Fehm, Tanja N.
in: GEBURTSH FRAUENHEILK, Jahrgang 78, Nr. 3, 03.2018, S. 246-259.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention
AU - Schneeweiss, Andreas
AU - Lux, Michael P
AU - Janni, Wolfgang
AU - Hartkopf, Andreas D
AU - Nabieva, Naiba
AU - Taran, Florin-Andrei
AU - Overkamp, Friedrich
AU - Kolberg, Hans-Christian
AU - Hadji, Peyman
AU - Tesch, Hans
AU - Wöckel, Achim
AU - Ettl, Johannes
AU - Lüftner, Diana
AU - Wallwiener, Markus
AU - Müller, Volkmar
AU - Beckmann, Matthias W
AU - Belleville, Erik
AU - Wallwiener, Diethelm
AU - Brucker, Sara Y
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Fehm, Tanja N
PY - 2018/3
Y1 - 2018/3
N2 - The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes play a major role, more and more new therapies for subgroups and histological subtypes are being developed, such as the use of PARP inhibitors to treat patients with BRCA mutations (breast and ovarian cancer). Supportive therapies are also evolving, allowing problems such as alopecia or nausea and vomiting to be treated more effectively. Treatment-related side effects have a direct impact on the prognosis of patients with metastatic breast cancer, and supportive therapy can improve compliance. Digital tools could be useful to establish better patient management systems. This overview provides an insight into recent trials and how the findings could affect routine treatment. Current aspects of breast cancer prevention are also presented.
AB - The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes play a major role, more and more new therapies for subgroups and histological subtypes are being developed, such as the use of PARP inhibitors to treat patients with BRCA mutations (breast and ovarian cancer). Supportive therapies are also evolving, allowing problems such as alopecia or nausea and vomiting to be treated more effectively. Treatment-related side effects have a direct impact on the prognosis of patients with metastatic breast cancer, and supportive therapy can improve compliance. Digital tools could be useful to establish better patient management systems. This overview provides an insight into recent trials and how the findings could affect routine treatment. Current aspects of breast cancer prevention are also presented.
KW - Journal Article
U2 - 10.1055/s-0044-101614
DO - 10.1055/s-0044-101614
M3 - SCORING: Journal article
C2 - 29576630
VL - 78
SP - 246
EP - 259
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 3
ER -